|

161Tb-DOTA-LM3 Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • University Hospital, Basel, Switzerland1

Indications

  • Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)1
  • Neuroendocrine Neoplasia's (NENs)1
  • Cancer1

Other1 trial

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.